Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage tumour cell cultures

European Journal of Cancer

Volumn 46, Issue 3, 2010, Pages 625-635

  Dias, João D ^a,b   Guse, Kilian ^a,b   Nokisalmi, Petri ^a,b   Eriksson, Minna ^a,b   Chen, Dung Tsa ^c   Diaconu, Iulia ^a,b   Tenhunen, Mikko ^b   Liikanen, Ilkka ^a,b   Grénman, Reidar ^d   Savontaus, Mikko ^d   Pesonen, Sari ^a,b   Cerullo, Vincenzo ^a,b   Hemminki, Akseli ^a,b  

^a Transplantation Laboratory   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF TURKU   (Finland)

Author keywords

Cancer gene therapy; Cetuximab; Chemotherapy; Oncolytic adenoviruses; Radiotherapy

Indexed keywords

CD133 ANTIGEN; CETUXIMAB; CISPLATIN; FLUOROURACIL; HERMES ANTIGEN; LUCIFERASE; ONCOLYTIC ADENOVIRUS; POLYLYSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL KILLING; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; FOLLOW UP; GENE TARGETING; GENE TRANSFER; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VIRUS CAPSID; VIRUS REPLICATION; WHOLE BODY RADIATION;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL DEATH; COMBINED MODALITY THERAPY; FEASIBILITY STUDIES; FEMALE; GENE TRANSFER TECHNIQUES; GLYCOPROTEINS; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; PEPTIDES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 75449096418     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.11.005     Document Type: Article

References (49)

1. Prince M.E., and Ailles L.E. Cancer stem cells in head and neck squamous cell cancer. J Clin Oncol 26 17 (2008) 2871-2875
2. Fuertesa M.A., Castillab J., Alonsoa C., and Perez J.M. Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem 10 3 (2003) 257-266
3. Pil P.M., and Lippard S.J. Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science 256 5054 (1992) 234-237
4. Rebillard A., Lagadic-Gossmann D., and Dimanche-Boitrel M.T. Cisplatin cytotoxicity: DNA and plasma membrane targets. Curr Med Chem 15 26 (2008) 2656-2663
5. Grem J.L. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs 18 4 (2000) 299-313
6. Noordhuis P., Holwerda U., Van der Wilt C.L., et al. 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. Ann Oncol 15 7 (2004) 1025-1032
7. Li L., Story M., and Legerski R.J. Cellular responses to ionizing radiation damage. Int J Radiat Oncol Biol Phys 49 4 (2001) 1157-1162
8. Pao W., Miller V.A., Politi K.A., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2 3 (2005) e73
9. Dempke W.C., and Heinemann V. Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. Eur J Cancer 45 7 (2009) 1117-1128
10. Reya T., Morrison S.J., Clarke M.F., and Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 414 6859 (2001) 105-111
11. Prince M.E., Sivanandan R., Kaczorowski A., et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 104 3 (2007) 973-978
12. Dean M., Fojo T., and Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 5 4 (2005) 275-284
13. Kanerva A., and Hemminki A. Modified adenoviruses for cancer gene therapy. Int J Cancer 110 4 (2004) 475-480
14. Anders M., Christian C., McMahon M., McCormick F., and Korn W.M. Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells. Cancer Res 63 9 (2003) 2088-2095
15. Bauerschmitz G.J., Guse K., Kanerva A., et al. Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells. Mol Ther 14 2 (2006) 164-174
16. Fueyo J., Gomez-Manzano C., Alemany R., et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19 1 (2000) 2-12
17. Sherr C.J. Cancer cell cycles. Science 274 5293 (1996) 1672-1677
18. Erjala K., Sundvall M., Junttila T.T., et al. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 12 13 (2006) 4103-4111
19. Ranki T., Kanerva A., Ristimaki A., et al. A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer. Gene Ther 14 1 (2007) 58-67
20. Rajecki M., Kiviharju-af Hallstrom T.M., Hakkarainen T., et al. Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiation. Int J Cancer 125 10 (2009) 2441-2449
21. Doody J.F., Wang Y., Patel S.N., et al. Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers. Mol Cancer Ther 6 10 (2007) 2642-2651
22. Dorr W., Bassler S., Reichel S., and Spekl K. Reduction of radiochemotherapy-induced early oral mucositis by recombinant human keratinocyte growth factor (palifermin): experimental studies in mice. Int J Radiat Oncol Biol Phys 62 3 (2005) 881-887
23. Chou T.-C.T.P. Analysis of combined drug effects: a new look at a very old problem. Trends Paramacol Sci 4 (1983) 450-454
24. Baumann M., Krause M., and Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 8 7 (2008) 545-554
25. Kish J.A., Ensley J.F., Jacobs J., et al. A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer 56 12 (1985) 2740-2744
26. Nyati M.K., Morgan M.A., Feng F.Y., and Lawrence T.S. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 6 11 (2006) 876-885
27. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. New Engl J Med 354 6 (2006) 567-578
28. Okegawa T., Li Y., Pong R.C., et al. The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. Cancer Res 60 18 (2000) 5031-5036
29. Hussein M.R., and Cullen K. Molecular biomarkers in HNSCC: prognostic and therapeutic implications. Expert Rev Anticancer Ther 1 1 (2001) 116-124
30. Khuri F.R., Nemunaitis J., Ganly I., et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6 8 (2000) 879-885
31. Lamfers M.L., Idema S., Bosscher L., et al. Differential effects of combined Ad5-delta 24RGD and radiation therapy in in vitro versus in vivo models of malignant glioma. Clin Cancer Res 13 24 (2007) 7451-7458
32. Vermorken J.B., Trigo J., Hitt R., et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25 16 (2007) 2171-2177
33. Vincenzi B., Schiavon G., Silletta M., Santini D., and Tonini G. The biological properties of cetuximab. Crit Rev Oncol Hematol 68 2 (2008) 93-106
34. Schmidt-Ullrich R.K., Valerie K., Fogleman P.B., and Walters J. Radiation-induced autophosphorylation of epidermal growth factor receptor in human malignant mammary and squamous epithelial cells. Radiat Res 145 1 (1996) 81-85
35. Schmidt-Ullrich R.K., Mikkelsen R.B., Dent P., et al. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 15 10 (1997) 1191-1197
36. Van Schaeybroeck S., Karaiskou-McCaul A., Kelly D., et al. Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res 11 20 (2005) 7480-7489
37. Dittmann K., Mayer C., Fehrenbacher B., et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 280 35 (2005) 31182-31189
38. Hart L.S., Yannone S.M., Naczki C., et al. The adenovirus E4orf6 protein inhibits DNA double strand break repair and radiosensitizes human tumor cells in an E1B-55K-independent manner. J Biol Chem 280 2 (2005) 1474-1481
39. Yan D.H., Chang L.S., and Hung M.C. Repressed expression of the HER-2/c-erbB-2 proto-oncogene by the adenovirus E1a gene products. Oncogene 6 2 (1991) 343-345
40. Bauerschmitz G.J., Ranki T., Kangasniemi L., et al. Tissue-specific promoters active in CD44+CD24-/low breast cancer cells. Cancer Res 68 14 (2008) 5533-5539
41. Eriksson M., Guse K., Bauerschmitz G., et al. Oncolytic adenoviruses kill breast cancer initiating CD44+CD24-/low cells. Mol Ther 15 12 (2007) 2088-2093
42. Kirn D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?. Gene Ther 8 2 (2001) 89-98
43. Aiuti A., Cattaneo F., Galimberti S., et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. New Engl J Med 360 5 (2009) 447-458
44. Yla-Herttuala S. Phase III trial: Ad-Tk gene therapy for malignant glioma. In: Therapy H.G. (Ed). ESGCT 2008 invited presentations (2008), Mary Ann Liebert Inc., Brugge 1060-1075
45. Kanerva A., Mikheeva G.V., Krasnykh V., et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 8 1 (2002) 275-280
46. Dmitriev I., Krasnykh V., Miller C.R., et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 72 12 (1998) 9706-9713
47. Wu H., Seki T., Dmitriev I., et al. Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency. Hum Gene Ther 13 13 (2002) 1647-1653
48. Kanerva A., Zinn K.R., Chaudhuri T.R., et al. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 8 3 (2003) 449-458
49. Suzuki K., Fueyo J., Krasnykh V., et al. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 7 1 (2001) 120-126